See all press releases
Category: tools invest
Financial reports 2026
Years First Quarter Second Quarter Third Quarter Fourth Quarter Interim Registration Document 2026 2025 URD (fr) 2024 URD (fr) 2023 URD (fr) Amendment(fr) 2022 URD (fr) 2021 … Continue reading Financial reports 2026
Annual General Meeting
Annual General Meeting of May 22, 2026 2026 ORDINARY AND EXTRAORDINARY MEETING Location: TRANSGENE 400 boulevard Gonthier d’Andernach – Parc d’Innovation 67400 ILLKIRCH-GRAFFENSTADEN – FRANCE Date and Time: May 22, 2026 at 11 am CET Webcast link to French language conference call (live and deferred) Documents Notice of 2026 Meeting Notice of the 2026… Continue reading Annual General Meeting
événements et presentations
Corporate presentation Financial calendar Webcasts Investor events
Analysts
Company Analyst E-mail Phone Kempen Chiara Montironi c.montironi@vanlanschotkempen.com + 31 610552719 Intron Health Naresh Chouhan naresh@intronhealthresearch.com +44 207 375 9143 Invest Securities Jamila El Bougrini jelbougrini@invest-securities.com +33 (0)1 44 88 88 09 Oddo BHF Martial Descoutures martial.descoutures@oddo-bhf.com +33 (0)1 44 51 85 00 Any opinions, forecasts, estimates, projections or predictions regarding Transgene’s performance made by… Continue reading Analysts
General
Stock price Follow Transgene’s share price and all its stock market news live on Euronext General Stock Market Euronext Paris – Eurolist (compartiment B) Reuters / Bloomberg TRNG.PA / TNG.FP ISIN Code FR0005175080 Total number of shares outstanding 274,186,709 Initial Public Offering (IPO) March 26, 1998 Local Sector Index Next Biotech Financial Year Ends December… Continue reading General
Stock Information
General arrow_downward Analysts arrow_downward
Financial information
Key figures arrow_downward Financial reports arrow_downward Regulated information arrow_downward
Key figures
In € million except share and per share data 2025 2024 2023 2022 2021 2020 2019 Revenue 7.2 6.4 7.9 10.3 17.4 9.9 13.7 R&D Expense -33.9 -34.3 -29.6 -32.2 -32.9 -27.3 -31.4 G&A Expense -7.3 -7.8 -7.0 -7.9 -7.4 -6.5 -7.1 Net income (loss) -37.5 -34 -22.3 -32.8 -19.5 -17.2 -18.8 Net Cash Burn… Continue reading Key figures
Regulated information
Transgene announces the success of its capital increase. Learn more about the details of the operation. The following pages contain information regarding the rights offering of Transgene. For regulatory reasons, the distribution of the content of this site is restricted. Consequently, please fill out the fields below to access the following pages. ➜ Learn More… Continue reading Regulated information